Isakova-Sivak Irina, Rudenko Larisa
a Department of Virology , Institute of Experimental Medicine , Saint Petersburg , Russia.
Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1333907. Epub 2017 May 26.
Avian-origin H7N9 influenza viruses first detected in humans in China in 2013 continue to cause severe human infections with a mortality rate close to 40%. These viruses are acknowledged as the subtype most likely to cause the next influenza pandemic. Areas covered: Here we review published data on the development of H7N9 influenza vaccine candidates and their evaluation in preclinical and clinical trials identified on PubMed database with the term 'H7N9 influenza vaccine'. In addition, a search with the same term was done on ClinicalTrials.gov to find ongoing clinical trials with H7N9 vaccines. Expert commentary: Influenza vaccines are the most powerful tool for protecting the human population from influenza infections, both seasonal and pandemic. During the past four years, a large number of promising H7N9 influenza vaccine candidates have been generated using traditional and advanced gene engineering techniques. In addition, with the support of WHO's GAP program, influenza vaccine production capacities have been established in a number of vulnerable low- and middle-income countries with a high population density, allowing the countries to be independent of vaccine supply from high-income countries. Overall, it is believed that the world is now well prepared for a possible H7N9 influenza pandemic.
2013年在中国首次在人类中检测到的禽源H7N9流感病毒继续导致严重的人类感染，死亡率接近40%。这些病毒被认为是最有可能引发下一次流感大流行的亚型。涵盖领域：在此，我们回顾了在PubMed数据库中以“H7N9流感疫苗”为关键词检索到的关于H7N9流感候选疫苗研发及其在临床前和临床试验中评估的已发表数据。此外，在ClinicalTrials.gov上使用相同关键词进行搜索，以查找正在进行的H7N9疫苗临床试验。专家评论：流感疫苗是保护人群免受季节性和大流行性流感感染的最有力工具。在过去四年中，利用传统和先进的基因工程技术已研发出大量有前景的H7N9流感候选疫苗。此外，在世卫组织全球行动计划的支持下，一些人口密度高的脆弱低收入和中等收入国家已建立了流感疫苗生产能力，使这些国家能够不依赖高收入国家的疫苗供应。总体而言，人们认为世界现在已为可能发生的H7N9流感大流行做好了充分准备。
